Patents by Inventor Kousei Yoshihara
Kousei Yoshihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9556160Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.Type: GrantFiled: March 27, 2015Date of Patent: January 31, 2017Assignee: Astellas Pharma Inc.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Hiroyoshi Yamada, Hisashi Mihara, Norio Seki
-
Publication number: 20150203480Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.Type: ApplicationFiled: March 27, 2015Publication date: July 23, 2015Applicant: Astellas Pharma Inc.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Hiroyoshi Yamada, Hisashi Mihara, Norio Seki
-
Patent number: 9051283Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.Type: GrantFiled: December 6, 2013Date of Patent: June 9, 2015Assignee: ASTELLAS PHARMA INC.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Hiroyoshi Yamada, Hisashi Mihara, Norio Seki
-
Patent number: 8802679Abstract: Compounds of formula (I) defined herein exhibit VAP-1 inhibitory activity, and as a result, are useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention.Type: GrantFiled: September 15, 2010Date of Patent: August 12, 2014Assignee: Astellas Pharma Inc.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
-
Patent number: 8716470Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.Type: GrantFiled: January 31, 2013Date of Patent: May 6, 2014Assignee: Astellas Pharma Inc.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Hiroyoshi Yamada, Hisashi Mihara, Norio Seki
-
Publication number: 20140100210Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.Type: ApplicationFiled: December 6, 2013Publication date: April 10, 2014Applicant: Astellas Pharma Inc.Inventors: Kousei YOSHIHARA, Daisuke SUZUKI, Susumu YAMAKI, Hiroyoshi YAMADA, Hisashi MIHARA, Norio SEKI
-
Publication number: 20120184520Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.Type: ApplicationFiled: September 15, 2010Publication date: July 19, 2012Applicant: Astellas Pharma Inc.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
-
Patent number: 7585886Abstract: [Problem] To provide a compound which may be used in treating diseases in which a calcium sensing receptor (CaSR) is concerned, particularly hyperparathyroidism. [Means for Resolution] It was found that novel pyrrolidine derivatives which are characterized by the possession of aminomethyl group substituted with arylalkyl group or the like, or salts thereof, have excellent CaSR agonistic regulatory activity and also have excellent selectivity with CYP2D6 inhibitory activity having a possibility of causing drug interaction. Based on the above, these novel pyrrolidine derivatives are useful as therapeutic agents for treating diseases in which CaSR is concerned (hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like).Type: GrantFiled: May 18, 2006Date of Patent: September 8, 2009Assignee: Astellas Pharma Inc.Inventors: Shunichiro Hachiya, Makoto Oku, Hana Mukai, Takashi Shin, Keisuke Matsuura, Ryushi Seo, Takashi Kamikubo, Yoh Terada, Masanao Sanagi, Kousei Yoshihara, Taisuke Takahashi
-
Publication number: 20090062366Abstract: [Problem] To provide a compound which may be used in treating diseases in which a calcium sensing receptor (CaSR) is concerned, particularly hyperparathyroidism. [Means for Resolution] It was found that novel pyrrolidine derivatives which are characterized by the possession of aminomethyl group substituted with arylalkyl group or the like, or salts thereof, have excellent CaSR agonistic regulatory activity and also have excellent selectivity with CYP2D6 inhibitory activity having a possibility of causing drug interaction. Based on the above, these novel pyrrolidine derivatives are useful as therapeutic agents for treating diseases in which CaSR is concerned (hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like).Type: ApplicationFiled: May 18, 2006Publication date: March 5, 2009Applicant: ASTELLAS PHARAMA INC.Inventors: Shunichiro Hachiya, Makoto Oku, Hana Mukai, Takashi Shin, Keisuke Matsuura, Ryushi Seo, Takashi Kamikubo, Yoh Terada, Masanao Sanagi, Kousei Yoshihara, Taisuke Takahashi
-
Patent number: 7442715Abstract: A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.Type: GrantFiled: August 17, 2006Date of Patent: October 28, 2008Assignee: Astellas Pharma Inc.Inventors: Akira Nagashima, Takayuki Inoue, Mitsuru Ohkubo, Kousei Yoshihara, Takashi Tojo, Masataka Morita
-
Publication number: 20080119462Abstract: The present invention provides a method for treating a vascular hyperpermeable disease (except macular edema), which method comprises administering to a patient in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease.Type: ApplicationFiled: October 31, 2007Publication date: May 22, 2008Applicants: Sucampo AG, Astellas Pharma Inc.Inventors: Ryuji UENO, Akira Nagashima, Takayuki Inoue, Mitsuru Ohkubo, Kousei Yoshihara
-
Publication number: 20060276521Abstract: A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.Type: ApplicationFiled: August 17, 2006Publication date: December 7, 2006Applicant: Astellas Pharma Inc.Inventors: Takayuki Inoue, Takashi Tojo, Masataka Morita, Mitsuru Ohkubo, Kousei Yoshihara, Akira Nagashima
-
Patent number: 7125901Abstract: A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.Type: GrantFiled: January 27, 2004Date of Patent: October 24, 2006Assignee: Astellas Pharma Inc.Inventors: Takayuki Inoue, Takashi Tojo, Masataka Morita, Mitsuru Ohkubo, Kousei Yoshihara, Akira Nagashima
-
Publication number: 20060128770Abstract: A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.Type: ApplicationFiled: February 2, 2006Publication date: June 15, 2006Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Takayuki Inoue, Takashi Tojo, Masataka Morita, Mitsuru Ohkubo, Kousei Yoshihara, Akira Nagashima
-
Publication number: 20040259923Abstract: A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.Type: ApplicationFiled: January 27, 2004Publication date: December 23, 2004Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Takayuki Inoue, Takashi Tojo, Masataka Morita, Mitsuru Ohkubo, Kousei Yoshihara, Akira Nagashima
-
Publication number: 20020132809Abstract: 1Type: ApplicationFiled: February 25, 2002Publication date: September 19, 2002Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Teruo Oku, Ichiro Shima, Takehiko Ohkawa, Kazuhiko Ohne, Tatsuya Zenko, Kousei Yoshihara, Hiroyuki Setoi
-
Patent number: 6008230Abstract: This invention relates to a quinoline compound of the formula: ##STR1## wherein R.sup.1 is a pyridyl group or aryl, each of which may be substituted with suitable substituent(s),A is --COHN-- or --NHCO--,n is an integer of 0 or 1, and ##STR2## is a group of the formula: ##STR3## In which R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined,and pharmaceutically acceptable salt thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prevention and/or the treatment of bone diseases caused by abnormal bone metabolism in human being or animals.Type: GrantFiled: April 14, 1998Date of Patent: December 28, 1999Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Teruo Oku, Yoshio Kawai, Shigeki Satoh, Hitoshi Yamazaki, Natsuko Kayakiri, Yasuharu Urano, Kousei Yoshihara, Noriko Yoshida
-
Patent number: 5858995Abstract: This invention relates to a novel heterocyclic compound represented by formula (I), wherein each symbol is as defined in the specification and a pharmaceutically acceptable salt thereof which are the inhibitors of bone resorption and bone metabolism, to processes for preparation thereof, to a pharmaceutical composition comprising the same and to a method for the treatment of diseases caused by abnormal bone metabolism in human being or an animal.Type: GrantFiled: October 25, 1996Date of Patent: January 12, 1999Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Yoshio Kawai, Hitoshi Yamazaki, Natsuko Kayakiri, Kousei Yoshihara, Takumi Yatabe, Teruo Oku